Gradient Denervation Technologies is developing a minimally invasive ultrasound-based catheter system for the transvascular treatment of pulmonary hypertension in heart failure patients. This technology targets elevated pulmonary vascular resistance, aiming to improve cardiovascular health and patient outcomes.
Funding
$15M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Heart failure patients often develop pulmonary hypertension due to elevated pulmonary vascular resistance, which worsens their cardiovascular health. Current treatments are limited, and many patients require invasive procedures with significant risks.
Solution
Gradient Denervation Technologies is developing a minimally invasive, ultrasound-based catheter system designed for transvascular pulmonary artery denervation. This system targets the nerves surrounding the pulmonary arteries to reduce pulmonary vascular resistance in heart failure patients. By selectively ablating these nerves using ultrasound energy delivered through a catheter, the technology aims to improve cardiac function and overall cardiovascular health without the need for open surgery. The investigational device is currently undergoing early feasibility studies to evaluate its safety and efficacy.
Target Audience
The primary target audience includes heart failure patients with WHO Group 2 pulmonary hypertension (pulmonary hypertension due to left heart disease) and the physicians who treat them, including interventional cardiologists and heart failure specialists.
Features
- Minimally invasive catheter-based delivery system
- Ultrasound-based energy for targeted nerve ablation
- Transvascular approach to access pulmonary arteries
- Designed to reduce pulmonary vascular resistance